Far East Orchard Limited
O10.SI : Singapore Exchange
1.000
0.00%
Share Price in SGD. As of 26 Jul 17:04:43 SGT
All
Chart
Key stats
- 52-Week HighSGD 1.060
- 52-Week LowSGD 0.985
- Market CapSGD 488M
- Avg Volume95K
- P/E Ratio (TTM)20.00
- Forward Dividend Yield4.0%
Share Price Performance
| O10.SI | Market
| |
|---|---|---|
| 1 Day | 0.00% | 0.24% |
| 5 Day | 0.00% | -0.31% |
| 1 Month | -0.99% | 2.49% |
| 6 Month | -1.96% | 9.02% |
| YTD | -1.96% | 6.08% |
| 1 Year | -3.85% | 6.50% |
| 5 Year | -14.53% | 9.82% |
Market Analysis
Analyst Ratings
There is no analyst rating data currently available for Far East Orchard Limited.
Valuation
Price to earnings (P/E) ratio
∞
17.8
Far East Orchard Limited's current P/E ratio of ∞x is higher than its historical average P/E ratio of 17.8x.
Price to book (P/B) ratio
0.4
0.4
Far East Orchard Limited's current P/B ratio of 0.4x is inline with its historical average P/B ratio of 0.4x.
Earnings
Earnings Highlights
1Q FY2024 Results Summary
Revenue: SGD 50.90M
Increased 10% Year-on-Year
The improvement is mainly contributed by the Purpose-Built Student Accommodation business from rental growth and the additional of a property to the portfolio in June 2023.
Net Profit: SGD 6.9M
Increased 47% Year-on-Year
The Hospitality segment continued to provide stable contributions. The Group's property development joint venture, Woods Square, delivered higher sales and leasing income, contributing to the Group's share of profit from the joint venture.
Outlook
Acquisition of UK’s largest independent PBSA operator Homes For Students Limited in April 2024 will boost the Group’s recurring income stream. Macroeconomic challenges persist, intensified by ongoing geoeconomic tensions, persistent inflationary pressures, and market volatility.
Sources: Far East Orchard Limited Financial Report
Earnings per share (EPS)
The latest earnings per share is $0.14, which is higher than the earnings per share of $0.05 in 2022.
Financials
Financial Statements
| 28 Feb 2024 | For period ending 31 Dec 2023 |
| 26 Jan 2024 | For period ending 31 Dec 2023 |
| 08 Aug 2023 | For period ending 30 Jun 2023 |
Annual Reports
| 09 Apr 2024 | For period ending 31 Dec 2023 |
| 09 Apr 2024 | For period ending 31 Dec 2023 |
News
Profile
Company Description
Far East Orchard Limited is a real estate company with a lodging platform that aims to achieve sustainable and recurring income through a diversified and balanced portfolio. Established since 1967, Far East Orchard has a track record in real estate development, investment and management across residential, commercial, hospitality and PBSA properties in Australia, Japan, Malaysia, Singapore, and the UK. Listed on the Mainboard of the Singapore Exchange, Far East Orchard is also a member of Far East Organization, Singapore’s largest private property developer.
Redefining itself through a strategic business transformation in 2012, Far East Orchard expanded into hospitality management business and invested in healthcare real estate. In 2015, it further diversified its real estate portfolio to include PBSA properties development and investment in the UK. In 2023, Far East Orchard celebrated its 10-year partnerships in the hospitality business with The Straits Trading Company Limited and Toga Group, Australia.
Far East Orchard’s hospitality arm, Far East Hospitality, together with the joint venture, TFE hotels, now owns over 10 assets and manages close to 100 properties with more than 16,600 rooms in Australia, Austria, Denmark, Germany, Hungary, Japan, Malaysia, New Zealand, Singapore, and Switzerland, featuring 10 distinct brands. Far East Orchard’s PBSA portfolio includes 3,687 beds across key cities in the UK. In 2022, Far East Orchard entered into a joint venture development in Bristol for the development of a 706- bed PBSA asset. With the joint venture development in Bristol and announced site development in Glasgow, totalling 979 beds, the Group’s total PBSA portfolio will grow to approximately 4,700 beds across 15 properties in the UK upon completion of the developments. Additionally, the Group holds a portfolio of purpose-built medical suites for lease and sale in Novena, Singapore’s premier medical hub.